Oracle Corporation vs ResMed Inc. — how do they compare? Oracle Corporation trades at $125.94 (market cap $365.96B), while ResMed Inc. trades at $193.21 (market cap $28.40B). The key difference: Oracle Corporation is far larger — about 12.9× ResMed Inc.'s market cap, and Oracle Corporation pays the higher dividend (1.57%). Which is the better fit depends on your goals.
| ORCL | RMD | |
|---|---|---|
Market Cap | $365.96B | $28.40B |
Sector | Technology | Health |
52-Week High | $328.33 | $293.73 |
52-Week Low | $121.37 | $182.82 |
Enterprise Value | $495.21B | $27.58B |
Dividend Yield | 1.57% | 1.23% |
Signals from Pluang's Aura AI — not financial advice
Oracle Corporation (ORCL) trades at $125.86, up 3.7% with strong recent earnings beats. The stock shows bearish technical signals but maintains robust fundamentals with 21.67% net margins and consistent revenue growth. Recent AI partnerships and infrastructure investments position Oracle as a key player in the enterprise cloud and AI markets, though high valuation multiples and significant debt levels warrant caution.
Oracle presents a compelling growth story driven by AI infrastructure demand, with analyst consensus strongly bullish (65% buy ratings) and a $253.30 price target representing significant upside. Key risks include high leverage, competitive pressures, and execution challenges in capital-intensive AI expansion. The upcoming Q2 2026 earnings report on June 10 will be critical for validating the AI growth narrative.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →